Today: 21 May 2026
Browse Category

NASDAQ:MIAX 31 December 2025

Stock Market Today

  • SpaceX Files for Largest IPO Ever, Aiming to Raise $80 Billion
    May 20, 2026, 7:07 PM EDT. Elon Musk's SpaceX has filed paperwork for an initial public offering (IPO) expected to be the largest in history, potentially raising about $80 billion. This would surpass Saudi Aramco's 2019 record of $29 billion and could value SpaceX at over $1 trillion. Musk controls 85% of voting power, potentially becoming the world's first trillionaire. The company, known for reusable rockets and its satellite internet service Starlink, merged with Musk's AI firm xAI last year and plans ambitious projects including orbital data centers and moon bases. The IPO highlights the growing investor interest in space and AI-related industries, possibly setting the tone for a wave of tech IPOs including OpenAI and Anthropic.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop